Brief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
30/04/2026 02:30
April 30 (Reuters) - Mesoblast Ltd MSB.AX: REPORTS QTRLY RYONCIL NET REVENUES OF $30.3 MILLION Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil